Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe mysterious loss of nose immune cells in aging

NCT ID NCT06039527

Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This observational study aims to understand why older adults lose certain immune cells (T cells) from their nasal passages, which may make them more prone to respiratory infections. Researchers will compare young adults (18-30), healthy older adults (65+), and frail older adults (65+) by taking nasal samples and blood tests. The goal is to uncover the mechanisms behind this cell loss and its link to infection risk, but this study does not test any treatment or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

125 people

The number who actually took part.

Started

Jan 2021

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population: Investigators will recruit participants from 3 groups: * healthy young adults (18-30 years, n=50) * vital older adults (\>65 years, n=60) * frail elderly (\>65 years, n=60). These will be consist of individuals without a history of recurrent respiratory infections or with \>2 self-reported episodes of respiratory infection in the past year. Frailty will be determined by a clinical frailty score. The Clinical Frailty Scale (CFS) is a scale that caretakers can use to identify level of frailty in older patients from 1 (very fit) through 9 (terminally ill). For the present study, "vital older patients" are defined as those with a CFS of 1-3 and "older patients living with frailty with a CFS of 4 or higher".

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: •Adults able and willing to provide informed consent. Specific inclusion criteria per group: * Young adults aged 18-30 years old * Healthy elderly aged \>65 years old * Frail elderly \>65 years old * Clinical Frailty score healthy elderly 1-3 * Clinical Frailty score frail elderly \>3 * Self-reported respiratory tract infection in previous year healthy elderly 0-1 * Self-reported respiratory tract infection in previous year frail elderly 0-1 or \>1 Exclusion Criteria: * Incompetence to provide informed consent prior or during study * Current smoker or \>40 pack year history * History of severe nose bleedings * Diagnosed with asthma, COPD or chronic rhinosinusitis * Use of inhalation corticosteroids or antibiotics in the past 6 weeks * Current use of anti-coagulants (to prevent nosebleeds). Platelet inhibitors like acetylsalicylzuur (Ascal) are allowed. * Respiratory tract infection or common cold in the past 2 weeks * Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency) * Life expectancy \<28 days in the opinion of study physician * Vaccination in the 2 months prior to study start. A potential subject that is only excluded from participation based on a recent vaccination will be asked to re-participate 2 months post vaccination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory tract infectious disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Respiratory tract infections

Contacts and locations

Locations

  • Leiden University Medical Center

    Leiden, South Holland, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.